Press Release

2 weeks ago

Egle Therapeutics receives €9.3 Million in State Funding Under the “Innovations in Biotherapies and Bioproduction” Call for Projects from France 2030

Egle Therapeutics receives significant non-dilutive funding to accelerate the clinical development of its lead immuno-oncology therapeutic candidate, EGL-001, as part of the “Innovations in Biotherapies and Bioproduction” call for projects…

3 months ago

EGLE Therapeutics Strengthens its Executive Leadership team with the Appointment of Christophe Quéva, Ph.D, as Chief Executive Officer

Paris, France, January 13th, 2025 – Egle Therapeutics, a clinical-stage biotechnology company advancing the next generation of regulatory T cell (Treg)-focused therapies for oncology and autoimmune diseases, today announced the…

5 months ago

Egle Therapeutics to share preclinical efficacy data for EGL-001, a CTLA-4/CD25 antagonist fusion protein at the Society for Immunotherapy of Cancer Meeting

Egle Therapeutics, a biotechnology company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, will present at the Society for Immunotherapy of Cancer Meeting…

7 months ago

EGLE Therapeutics Strengthens its Board of Directors with the Appointment of Michel Detheux, Ph.D, as Independent Chairman Board Member, and with the Appointment of Mojgan Hossein-Nia, Ph.D. as Board member representative of Takeda Ventures

EGLE Therapeutics Strengthens its Board of Directors with the Appointment of Michel Detheux, Ph.D, as Independent Chairman Board Member, and with the Appointment of Mojgan Hossein-Nia, Ph.D. as Board member…

9 months ago

Egle Therapeutics to share preclinical data for its first autoimmune disease program, EGL-003, with an oral presentation at the 2024 Promise of Interleukin-2 Therapy Meeting

Egle Therapeutics, a biotechnology company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, will deliver an oral presentation at The Promise of Interleukin-2…

11 months ago

EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member

EGLE Therapeutics, a clinical-stage biotechnology company uniquely positioned to advance the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, announced today the appointment of Pejvack Motlagh MD,…

12 months ago

Egle Therapeutics to present novel immunocytokine preclinical data for EGL-001 with poster presentation at the 2024 AACR Annual Meeting

In the poster, entitled “EGL-001 is a novel immunocytokine designed to specifically target and disarm T regulatory cells in the tumor microenvironment”. Egle scientists present evidence that EGL-001, a CTLA-4…

1 year ago

Egle Therapeutics Strengthens its Leadership Team with the Appointment of Monica Gostissa, PhD, as Chief Scientific Officer and Reno Winter, PhD, as Chief Technical Officer

Paris, France, March 27th, 2024, Egle Therapeutics, a biotechnology company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto- immunity, announced today the appointment…

3 years ago

Egle Therapeutics appoints Pierre Legault as Chairman and Board Member

Paris, France, 5th May 2022 / Egle Therapeutics SAS (Egle), an emerging biotechnology company dedicated to developing novel immunotherapies for oncology and autoimmune diseases, is pleased to announce Pierre Legault…